Host: |
Rabbit |
Applications: |
WB/ELISA |
Reactivity: |
Human/Rat/Mouse |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-Growth/differentiation factor 3 (311-360 aa) is suitable for use in Western Blot and ELISA research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
Concentration: |
1 mg/mL |
Dilution Range: |
WB 1:500-1:2000ELISA 1:10000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
GDF3 |
Gene ID: |
9573 |
Uniprot ID: |
GDF3_HUMAN |
Immunogen Region: |
311-360 aa |
Specificity: |
GDF-3 Polyclonal Antibody detects endogenous levels of GDF-3 protein. |
Immunogen: |
Synthesized peptide derived from Growth/differentiation factor 3 at the amino acid range 311-360 |
Function | Growth factor involved in early embryonic development and adipose-tissue homeostasis. During embryogenesis controls formation of anterior visceral endoderm and mesoderm and the establishment of anterior-posterior identity through a receptor complex comprising the receptor ACVR1B and the coreceptor CRIPTO. Regulates adipose-tissue homeostasis and energy balance under nutrient overload in part by signaling through the receptor complex based on ACVR1C and CRIPTO/Cripto. |
Protein Name | Growth/Differentiation Factor 3Gdf-3 |
Cellular Localisation | SecretedCytoplasmMainly Accumulated In The Cytoplasm |
Alternative Antibody Names | Anti-Growth/Differentiation Factor 3 antibodyAnti-Gdf-3 antibodyAnti-GDF3 antibodyAnti-UNQ222 antibodyAnti-PRO248 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance